Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Hummel HD, Kufer P, Grüllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, Goebeler ME, Miller K, de Santis M, Loidl W, Dittrich C, Buck A, Lapa C, Thurner A, Wittemer-Rump S, Koca G, Boix O, Döcke WD, Finnern R, Kusi H, Ajavon-Hartmann A, Stienen S, Sayehli CM, Polat B, Bargou RC. Hummel HD, et al. Among authors: stienen s. Immunotherapy. 2021 Feb;13(2):125-141. doi: 10.2217/imt-2020-0256. Epub 2020 Nov 10. Immunotherapy. 2021. PMID: 33172323 Clinical Trial.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
Kebenko M, Goebeler ME, Wolf M, Hasenburg A, Seggewiss-Bernhardt R, Ritter B, Rautenberg B, Atanackovic D, Kratzer A, Rottman JB, Friedrich M, Vieser E, Elm S, Patzak I, Wessiepe D, Stienen S, Fiedler W. Kebenko M, et al. Among authors: stienen s. Oncoimmunology. 2018 Apr 18;7(8):e1450710. doi: 10.1080/2162402X.2018.1450710. eCollection 2018. Oncoimmunology. 2018. PMID: 30221040 Free PMC article.
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Penny HL, Hainline K, Theoharis N, Wu B, Brandl C, Webhofer C, McComb M, Wittemer-Rump S, Koca G, Stienen S, Bargou RC, Hummel HD, Loidl W, Grüllich C, Eggert T, Tran B, Mytych DT. Penny HL, et al. Among authors: stienen s. Front Immunol. 2023 Oct 23;14:1261070. doi: 10.3389/fimmu.2023.1261070. eCollection 2023. Front Immunol. 2023. PMID: 37942314 Free PMC article.
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
Suurs FV, Lorenczewski G, Bailis JM, Stienen S, Friedrich M, Lee F, van der Vegt B, de Vries EGE, de Groot DA, Lub-de Hooge MN. Suurs FV, et al. Among authors: stienen s. J Nucl Med. 2021 Apr 30;62(12):1797-804. doi: 10.2967/jnumed.120.259036. Online ahead of print. J Nucl Med. 2021. PMID: 33931466 Free PMC article.
CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Xu Y, Fu J, Henderson M, Lee F, Jurcak N, Henn A, Wahl J, Shao Y, Wang J, Lyman M, Funes V, Espinoza B, Zhang R, Washington I, Chen SY, Zlomke H, Wang J, Niu N, Li P, Meng F, Burns W, Friedrich M, Stienen S, Bailis JM, Zheng L. Xu Y, et al. Among authors: stienen s. Gastroenterology. 2023 Nov;165(5):1219-1232. doi: 10.1053/j.gastro.2023.06.037. Epub 2023 Jul 26. Gastroenterology. 2023. PMID: 37507075 Free article.
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G, Latuske E, Bokemeyer C, Kischel R, Dos Santos C, Stienen S, Friedrich M, Lutteropp M, Nagorsen D, Wellbrock J, Fiedler W. Stamm H, et al. Among authors: stienen s. Oncogene. 2018 Sep;37(39):5269-5280. doi: 10.1038/s41388-018-0288-y. Epub 2018 May 31. Oncogene. 2018. PMID: 29855615 Free PMC article.
39 results